BioNTech wins US$445 million German grant for COVID-19 vaccine

BioNTech wins US$445 million German grant for COVID-19 vaccine

FILE PHOTO: The headquarters of biopharmaceutical company BioNTech are seen in Mainz
FILE PHOTO: The headquarters of biopharmaceutical company BioNTech are seen in Mainz, Germany July 31, 2018. REUTERS/Ralph Orlowski

BERLIN: German biotech firm BioNTech said on Tuesday (Sep 15) it had secured almost US$450 million in government funding to speed up work on its COVID-19 vaccine candidate and expand its production capacity in Germany.

BioNTech and partners Pfizer Inc and China's Shanghai Fosun Pharmaceutical Group Co Ltd are among the leading developers of experimental COVID-19 vaccines, based on molecules carrying a genetic code called messenger RNA (mRNA).

Mainz-based BioNTech, founded in 2008 and listed on the Nasdaq exchange last year, said it had been awarded 375 million euros (US$445 million) in funding, after applying under a scheme announced in July by Research Minister Anja Karliczek.

It will use the money, which is subject to it reaching certain clinical milestones, to finance part of its COVID-19 vaccine development programme, which it calls BNT162.

"The funding is an important contribution to accelerate the development and expansion of our production capacity for a COVID 19 vaccine in Germany," said Ugur Sahin, CEO and co-founder of BioNTech.

The company said it was one of three vaccine programmes to be awarded funding from a government pot of 750 million euros that aims to expand production capacity in Germany and increase the number of people involved in late-stage testing.

Fellow German biotech firm CureVac said earlier this month it had been awarded 252 million euros in government to support its vaccine candidate..

BioNTech and Pfizer are already testing their most promising vaccine candidate in late-stage trials and have started recruiting patients in the United States, Brazil, Argentina and Europe.

BOOKMARK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak: https://cna.asia/telegram

Source: Reuters/nh

Bookmark